Sting activators as therapy for cancer
Ended Project Grant Awarded Last action
- Award ID
- R42CA250629
- Recipient
-
Stinginn, LLC UEI PJV5A55KF6T5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,980,319
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- Florida, USA
Award details come from USAspending.gov.
Description
- Abstract
- The immuno-oncology (IO) arena affords a new and exciting approach to stimulate the body's own immune system to fight cancer. The generation of anti-cancer t cells is predominantly triggered by phagocytosed cancer cells stimulating innate immune signaling pathways in professional antigen presenting cells (APC's). This signaling process is largely governed by sting (stimulator of interferon genes), a cellular protein discovered by the laboratory of DR. Glen n. Barber that plays an essential role in host defense against infectious disease and cancer. Activation of sting triggers cytokine production and facilitates tumor antigen cross-presentation. Indeed, considerable effort is now underway in the biotech arena to discover techniques to augment sting activity with the objective of invigorating the generation of anti-tumor cytotoxic t cells. Along with check-point inhibitors and car-t cell therapy, the plausible utilization of sting agonists affords a new, complementary immunotherapeutic strategy to treat malignant disease. Here, stinginn, LLC ("stinginn"), in collaboration with the university of miami, proposes to perform an FDA approved investigator sponsored small phase i clinical trial for patients suffering from highly aggressive leukemias, specifically relapsed/refractory acute myeloid leukemia (AML) and adult lymphocytic leukemia (all) focusing on htlv-1 associated adult t cell lymphocytic leukemia (atll). Our strategy involves reinfusing autologous tumor cells loaded with sting-dependent adjuvants (stavs) into patients to stimulate apcs in vivo and thus anti-tumor CTL's. Our pre-clinical data indicates that stav loaded cells are highly immunogenic, potent activators of APC's. We have already submitted an IND FDA application based on this work and have assembled an appropriate team to carry out the proposed trial. Our proposal is also applicable to a variety of cancers, not just leukemia, providing the opportunity to initiate a number of alternate cancer therapeutic trials in the future.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $993,879 | |
| Amendment | $993,220 | |
| Original award | $993,220 |
Quick answers
Who received award R42CA250629?
R42CA250629 was awarded to Stinginn, LLC by National Cancer Institute (National Institutes of Health) on September 17, 2020.
How much is award R42CA250629 worth?
$2,980,319 has been obligated on R42CA250629.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award